DE69431843D1 - Il-8 inhibitoren - Google Patents

Il-8 inhibitoren

Info

Publication number
DE69431843D1
DE69431843D1 DE69431843T DE69431843T DE69431843D1 DE 69431843 D1 DE69431843 D1 DE 69431843D1 DE 69431843 T DE69431843 T DE 69431843T DE 69431843 T DE69431843 T DE 69431843T DE 69431843 D1 DE69431843 D1 DE 69431843D1
Authority
DE
Germany
Prior art keywords
inhibitors
receptor
binding
compete
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431843T
Other languages
English (en)
Other versions
DE69431843T2 (de
Inventor
A Tekamp-Olson
Guy Mullenbach
Ellen Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69431843D1 publication Critical patent/DE69431843D1/de
Application granted granted Critical
Publication of DE69431843T2 publication Critical patent/DE69431843T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69431843T 1993-09-14 1994-09-13 Il-8 inhibitoren Expired - Lifetime DE69431843T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/121,105 US6448379B1 (en) 1993-09-14 1993-09-14 IL8 inhibitors
PCT/US1994/010356 WO1995007934A2 (en) 1993-09-14 1994-09-13 Il8 inhibitors

Publications (2)

Publication Number Publication Date
DE69431843D1 true DE69431843D1 (de) 2003-01-23
DE69431843T2 DE69431843T2 (de) 2003-07-10

Family

ID=22394586

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69431843T Expired - Lifetime DE69431843T2 (de) 1993-09-14 1994-09-13 Il-8 inhibitoren
DE69435083T Expired - Lifetime DE69435083T2 (de) 1993-09-14 1994-09-13 Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69435083T Expired - Lifetime DE69435083T2 (de) 1993-09-14 1994-09-13 Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen

Country Status (11)

Country Link
US (2) US6448379B1 (de)
EP (3) EP1932856A3 (de)
JP (3) JPH09502725A (de)
AT (2) ATE229036T1 (de)
AU (1) AU697190B2 (de)
CA (1) CA2171289C (de)
DE (2) DE69431843T2 (de)
DK (1) DK1283217T3 (de)
ES (1) ES2302774T3 (de)
PT (1) PT1283217E (de)
WO (1) WO1995007934A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000893A1 (en) * 1995-06-20 1997-01-09 Chiron Corporation Interleukin-8 receptor binding compounds
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
AU777766B2 (en) * 1996-07-05 2004-10-28 Cancer Research Technology Limited Inhibitors of the interaction between p53 and MDM2
EP0939634A4 (de) * 1996-08-15 2001-02-21 Smithkline Beecham Corp Il-8 rezeptor antagonisten
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
ES2156534B1 (es) * 1999-02-03 2002-02-01 Smithkline Beecham Sa Nuevos inhibidores de la interaccion entre la interleuquina-8 y sus receptores
EP1268554A2 (de) * 2000-03-31 2003-01-02 IPF Pharmaceuticals GmbH Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EA037063B1 (ru) 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2-связывающие полипептиды
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
CN109890364B (zh) * 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗
MX2020006171A (es) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
JP7429427B2 (ja) 2020-01-31 2024-02-08 株式会社大都技研 抽出装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
JP2866182B2 (ja) 1990-10-08 1999-03-08 日本ケミファ株式会社 エンドセリン受容体
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5571702A (en) * 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
EP0579739A4 (de) * 1991-04-10 1994-03-22 Univ Boston Interleukin-8-rezeptoren, damit in zusammenhang stehende moleküle und verfahrensweisen.
US5374506A (en) * 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor

Also Published As

Publication number Publication date
WO1995007934A2 (en) 1995-03-23
ATE229036T1 (de) 2002-12-15
PT1283217E (pt) 2008-06-11
JP2005023085A (ja) 2005-01-27
CA2171289C (en) 2007-04-10
DE69435083T2 (de) 2009-03-12
US6436390B1 (en) 2002-08-20
AU697190B2 (en) 1998-10-01
EP1283217B1 (de) 2008-03-05
DK1283217T3 (da) 2008-07-07
EP1283217A3 (de) 2003-09-17
JPH09502725A (ja) 1997-03-18
WO1995007934A3 (en) 1995-04-13
CA2171289A1 (en) 1995-03-23
EP0719285A1 (de) 1996-07-03
EP1283217A2 (de) 2003-02-12
EP1932856A3 (de) 2009-09-30
ES2302774T3 (es) 2008-08-01
ATE388168T1 (de) 2008-03-15
EP0719285B1 (de) 2002-12-04
DE69431843T2 (de) 2003-07-10
JP2008169227A (ja) 2008-07-24
JP4122321B2 (ja) 2008-07-23
DE69435083D1 (de) 2008-04-17
EP1932856A2 (de) 2008-06-18
US6448379B1 (en) 2002-09-10
AU7834894A (en) 1995-04-03

Similar Documents

Publication Publication Date Title
DE69431843D1 (de) Il-8 inhibitoren
ES2304795T3 (es) Anticuerpos agonistas para el receptor de trombopoyetina y sus usos terapeuticos.
EP0741748A4 (de) Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung
BR0315123A (pt) Composições farmacêuticas direcionadas a receptores erb-b1
HU9402823D0 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
ATE247667T1 (de) Gdnf-rezeptor und dessen verwendung
CY1107133T1 (el) Κυκλικοι ανταγωνιστες των υποδοχεων c5a και συζευγμενοι με πρωτεϊνη g υποδοχεις
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
DK0457804T3 (da) M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
ATE312915T1 (de) Neurturin-rezeptor
DE69633131D1 (de) Rezeptor des y-y5 neuropeptids
CY1109583T1 (el) Κυτοκινες θηλαστικων, αντιστοιχα αντιδραστηρια
MXPA02008462A (es) Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis.
IT1277827B1 (it) Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
ATE309371T1 (de) Protein mit dnase-aktivität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US